Lanreotide Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: Angiopeptin, BIM-23014, DC 13116, Dermopeptin, Ipstyl +2 more

Pipeline

Phase 3: 2Phase 1/2: 1

Top Sponsors

SWOG Cancer Research Network1
RayzeBio, Inc.1
National Health Research Institutes, Taiwan1

Indications

Cancer3
Neuroendocrine Tumors,Gastroenteropancreatic1
Pancreatic NET1
Carcinoid1
Gastroenteropancreatic Neuroendocrine Tumor Disease1

Other1 trial

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Phase 1/2

Birmingham, Alabama1 trial

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

University of Alabama at Birmingham Cancer Center

Phase 3

Phoenix, Arizona1 trial

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Research Facility

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.